Rare molecule detection

Patent metadata

Field	Value
Publication number	US-10809264-B2
Application number	US-201515314860-A
Country	US
Kind code	B2
Filing date	May 29, 2015
Priority date	May 29, 2014
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.

First claim

What is claimed is:

1. A method of detecting one or more different populations of target rare molecules in a sample suspected of containing the one or more different populations of rare molecules and non-rare molecules, the method comprising:
(a) enhancing the concentration of the one or more different populations of target rare molecules over that of the non-rare molecules to form a concentrated sample,
(b) incubating the concentrated sample with, for each different population of target rare molecules, an affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule of one of the populations of the target rare molecules wherein the affinity agent comprises a mass spectrometry label precursor or a first alteration agent with a mass spectrometry label precursor and wherein the affinity agent may be non-particulate or particulate and wherein the first alteration agent either facilitates the formation of a mass spectrometry label from the mass spectrometry label precursor or releases an entity that comprises the mass spectrometry label precursor from the affinity agent,
(c) forming a retentate and a filtrate by contacting the incubated sample with a porous matrix,
(d) if the first alteration agent does not facilitate the formation of a mass spectrometry label from the mass spectrometry label precursor, then subjecting one or both of the retentate and the filtrate to a second alteration agent that facilitates the formation of a mass spectrometry label from the mass spectrometry label precursor from the affinity agent,
(e) subjecting one or both of the retentate and the filtrate to mass spectrometry analysis to determine the presence and/or amount of each different mass spectrometry label, and
(f) relating the presence and/or amount of each different mass spectrometry label to the present and/or amount of each different population of target rare molecules in the sample.

2. The method according to claim 1 , wherein the specific binding partner of the affinity agent is selected from the group consisting of antibodies and nucleic acids.

3. The method according to claim 1 , wherein at least one different population of the target rare molecules is associated with rare cells.

4. The method of claim 3 , wherein the rare cells are human cells, bacterial cells or viral cells.

5. The method according to claim 1 , wherein the affinity agent is particulate and comprises at least one carrier particle to which is linked at least one label particle wherein the label particle comprises a mass spectrometry label precursor.

6. The method according to claim 5 , wherein the affinity reagent comprises more than one carrier particle wherein each of the carrier particles is linked to one another by a linking group.

7. The method according to claim 5 wherein the affinity agent, carrier particle, label particle and mass spectrometry label precursor are connected by at least one linking group.

8. The method according to claim 7 wherein the linking group is cleavable.

9. The method according to claim 5 wherein the carrier particle, label particle, linking group or mass spectrometry label precursor is fluorescent.

10. The method according to claim 5 , wherein the carrier particle or the label particle is magnetic.

11. The method according to claim 5 , wherein the label particle is magnetic and is removed from the membrane by punching out, filtration, extraction, or pickup.

12. The method according to claim 1 , wherein step (c) comprises disposing the concentrated sample on a side of a porous matrix and applying vacuum to the disposed concentrated sample wherein the vacuum applied is about 1 millibar to about 100 millibar and wherein the pore size of the porous matrix is about 1 μm to about 100 μm.

13. A method of detecting one or more different populations of target rare cells in a sample suspected of containing the one or more different populations of rare cells and non-rare cells, the method comprising:
(a) enhancing the concentration of the one or more different populations of target rare cells over that of the non-rare cells to form a concentrated sample,
(b) incubating the concentrated sample with, for each different population of target rare cells, a mass spectrometry label precursor and an alteration agent that facilitates the formation of a mass spectrometry label from the mass spectrometry label precursor wherein the mass spectrometry label precursor or the alteration agent is part of an affinity agent that is specific for a target rare cell of one of the populations of the target rare cells,
(c) disposing the concentrated sample on a side of a porous matrix and applying vacuum to the disposed concentrated sample to form a retentate and a filtrate,
(d) subjecting one or both of the retentate and the filtrate to mass spectrometry analysis to determine the presence and/or amount of each different mass spectrometry label, and
(e) relating the presence and/or amount of each different mass spectrometry label to the present and/or amount of each different population of target rare cells in the sample.

14. The method according to claim 13 , wherein the affinity agent is selected from the group consisting of antibodies and nucleic acids.

15. The method according to claim 13 , wherein the alteration agent acts to facilitate cleavage of the mass spectrometry label precursor to form the mass spectrometry label or wherein the alteration agent acts to facilitate reaction of the mass spectrometry label precursor with a moiety to form the mass spectrometry label.

16. A method of detecting one or more different populations of target rare molecules in a sample suspected of containing the one or more different populations of rare molecules and non-rare molecules, the method comprising:
(a) incubating (i) a sample that has an enhanced concentration of the one or more different populations of target rare molecules over that of the non-rare molecules wherein the target rare molecules are in particulate form, and (ii) for each different population of target rare molecules, an affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule of one of the populations of the target rare molecules wherein the affinity agent comprises a mass spectrometry label precursor or a first alteration agent with a mass spectrometry label precursor and wherein, for each different population of target rare molecules, the affinity agent comprises a particle reagent and wherein the first alteration agent either facilitates the formation of a mass spectrometry label from the mass spectrometry label precursor or releases an entity that comprises the mass spectrometry label precursor from the affinity agent, and wherein, during the incubating, for each different population of target rare molecules, particle aggregates are formed from the particle reagent of the affinity agent,
(b) forming a retentate and a filtrate by contacting the incubated sample with a porous matrix,
(c) if the first alteration agent does not facilitate the formation of a mass spectrometry label from the mass spectrometry label precursor, then subjecting one or both of the retentate and the filtrate to a second alteration agent that facilitates the formation of a mass spectrometry label from the mass spectrometry label precursor from the affinity agent for each different population of target rare molecules,
(d) subjecting one or both of the retentate and the filtrate to mass spectrometry analysis to determine the presence and/or amount of each different mass spectrometry label, and
(e) rel

Assignees

• Siemens Healthcare Diagnostics Inc

Inventors

• Pugia Michael
• Philip Julia
• Marfurt Karen

Classifications

• G01N33/6848 Primary

  Methods of protein analysis involving mass spectrometry · CPC title

• G01N2001/4088

  filtration · CPC title

• G01N33/585 Primary

  with a particulate label, e.g. coloured latex · CPC title

• G01N2560/00

  Chemical aspects of mass spectrometric analysis of biological material · CPC title